Brief: Zelira Therapeutics To Receive An Upfront, Non-Refundable, Non-Contingent Licensing Fee Of Us$1 Million

Zelira Therapeutics

03/11/2021 01:56

Nov 3 (Reuters) - Zelira Therapeutics Ltd  ZLD.AX :
    * ZELIRA TO RECEIVE AN UPFRONT, NON-REFUNDABLE,
NON-CONTINGENT
LICENSING FEE OF US$1 MILLION
    * FOUNDATIONAL LICENSING DEAL FOR EDCDM TECHNOLOGY SIGNED
WITH
DRCN HOLDINGS

Source text for Eikon:  ID:nASX8SMTPK 
Further company coverage:  ZLD.AX 

 ((Reuters.Briefs@thomsonreuters.com;))